A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of ...

This innovative treatment could offer a major breakthrough for patients struggling with elevated Lp (a). Credit: Tada Images ...

Lp (a) is a genetically driven variant of low-density lipoprotein (LDL) cholesterol, that is known to be an independent risk ...

The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited ...

Muvalaplin is an investigational, oral, small-molecule inhibitor that targets Lp(a), a lipoprotein linked to increased cardiovascular disease risk. Elevated Lp(a) levels are associated with a ...

Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.

Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research, said Eli Lilly is weighing next steps for ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...